Journal Article > ResearchFull Text
PLoS Negl Trop Dis. 25 May 2018; Volume 12 (Issue 5); DOI:10.1371/journal.pntd.0006527
Abongomera C, Diro EGJ, de Lima Pereira A, Buyze J, Stille K, et al.
PLoS Negl Trop Dis. 25 May 2018; Volume 12 (Issue 5); DOI:10.1371/journal.pntd.0006527
North-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-infection. VL-HIV co-infected patients have higher (initial) parasitological failure and relapse rates than HIV-negative VL patients. Whereas secondary prophylaxis reduces the relapse rate, parasitological failure rates remain high with the available antileishmanial drugs, especially when administered as monotherapy. We aimed to determine the initial effectiveness (parasitologically-confirmed cure) of a combination of liposomal amphotericin B (AmBisome) and miltefosine for treatment of VL in HIV co-infected patients.